Skip Navigation


European Heart Journal Advance Access originally published online on October 11, 2005
European Heart Journal 2005 26(22):2354-2355; doi:10.1093/eurheartj/ehi554
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
26/22/2354    most recent
ehi554v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in EHJ
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Boersma, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Boersma, E.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The European Society of Cardiology 2005. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Direct thrombin inhibitors in acute coronary syndrome patients undergoing percutaneous coronary intervention: special effects in selected patients?

Eric Boersma*

Clinical Epidemiology Unit, Thoraxcenter Cardiology, Room Ba563, Erasmus MC, Dr Molewaterplein 40, 3015 GD Rotterdam, The Netherlands

* Corresponding author. Tel: +31 10 463 2307; fax: +31 10 408 9484. E-mail address: h.boersma@erasmusmc.nl

This editorial refers to ‘Direct thrombin inhibitors in acute coronary syndromes: effects in patients undergoing early percutaneous coronary intervention’{dagger} by P.R. Sinnaeve et al., on page 2396

The first 10% of the full text of this article appears below.

Coronary thrombosis is a pivotal event in the pathogenesis of acute coronary syndromes (ACS) as well as in the incidence of thrombotic complications resulting from percutaneous coronary interventions (PCIs).1 Platelet adhesion and aggregation at the site of spontaneous or provoked plaque rupture is an important contributor of such intracoronary thrombus formation. As activation of the platelet glycoprotein (GP) IIb/IIIa receptor is the final common pathway in the process leading to platelet aggregation, inhibitors of the platelet GP IIb/IIIa are potent agents to prevent progression to myocardial infarction (MI) and death. In a recent meta-analysis of six phase III randomized trials, which enrolled 31 402 ACS patients without ST-elevation who were not scheduled for early PCI, GP IIb/IIIa inhibitors were associated . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in EHJ:

Direct thrombin inhibitors in acute coronary syndromes: effect in patients undergoing early percutaneous coronary intervention
Peter R. Sinnaeve, John Simes, Salim Yusuf, Jyotsna Garg, Shamir Mehta, John Eikelboom, John A. Bittl, Patrick Serruys, Eric J. Topol, and Christopher B. Granger
EHJ 2005 26: 2396-2403. [Abstract] [Full Text]